Ingen internetforbindelse — viser den gemte version af siden.

Sanofi ADR

USUSD
← Til Screeneren

Sanofi ADR (US:SNYNF) — Biotechnology: Pharmaceutical Preparations. Antal børser, hvor selskabets aktier handles: 6. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.

Om Virksomheden

Websted
sanofi.com
Investorrelationer
sanofi.com/en/investors
Sektor
Health Care · Biotechnology: Pharmaceutical Preparations
Hovedkontor
PARIS, France
Administrerende Direktør
Paul Hudson
Ansatte
106 566
Grundlagt
2004
Udestående Aktier
1.22 mia. pr. 2025-12-31
Free Float
2.16 mia.
Markedsværdi
98.67 mia. USD
Insidere
0%
Institutionelle Investorer
8.02%
Branche (SIC)
Pharmaceutical Preparations
Juridisk Form
QVPB
ISIN
FR0000120578
LEI
549300E9PC51EN656011
Udbetalingsgrad
≈64.0%
FCF
10.8 mia. EUR
Udbetaling / FCF
47%
Gæld
18.7 mia. EUR
1.0 år FCF
Udbyttestreak
23 år
Indtjening, FCF og udbetalt udbytte — for de 12 måneder frem til 31.12.2025 (selskabets seneste rapport).
NAV
58.53 EUR · P/NAV 1.14
Balancedato31.12.2025
Aktiver127 mia. EUR
− Forpligtelser55.1 mia. EUR
= Total Egenkapital71.7 mia. EUR
− Ikke-Kontrollerende Interesser334 mio. EUR
= NAV (aktiekapital i selskabets aktionærer)71.4 mia. EUR
− Goodwill41.3 mia. EUR
− Immaterielle Aktiver26.3 mia. EUR
= Materiel NAV3.82 mia. EUR
Aktier1 219 427 096
NAV pr. Aktie58.53 EUR
Håndgribelig NAV pr. Aktie3.13 EUR
Aktiekurs (SNYNF)78.5500 USD
P/NAV1.14
NAV-Historie
BalancedatoNAVNAV pr. Aktie
31.12.202571.4 mia. EUR58.53 EUR
31.12.202477.5 mia. EUR61.36 EUR
31.12.202374.0 mia. EUR58.54 EUR
31.12.202274.8 mia. EUR59.31 EUR
31.12.202168.7 mia. EUR54.36 EUR
31.12.202063.1 mia. EUR50.46 EUR
31.12.201959.1 mia. EUR47.10 EUR
31.12.201858.9 mia. EUR47.27 EUR
Beskrivelse

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

annonce

Børser og Tickere

BørsTickerValutaPrisType
US USA StocksSNYNF OTCUSD78.55 +0.49%almindelige aktier
LSE London Stock Exchange0O59 IOBEUR71.63 +0.72%almindelige aktier
MI Borsa Italiana (Milan)1SAN sekundærEUR71.64 -1.02%almindelige aktier
PA Euronext ParisSAN primærEUR72.06 -0.14%almindelige aktier
VI Vienna Stock ExchangeSANO sekundærEUR71.3 +1.03%almindelige aktier
XETRA XetraSNW sekundærEUR71.78 -1.21%almindelige aktier

Kurs over 3 Måneder

stigningsdag faldsdag udbyttets ex-dato udbetalingsdatoHold musen over / tryk på en dag — åbnings-, luknings-, højeste og laveste kurs

Udbytte

Pr. År, US:SNYNF: 4.12 EUR (1 udb.)

Sanofi ADR (SNYNF) udbetaler udbytte én gang om året. Pr. År (12 måneder op til og med den senest annoncerede betaling): 4.12 EUR pr. Aktie (betalinger: 1). Baseret på betalingshistorikken forventes næste ex-udbyttedato omkring 06.05.2027. Uafbrudt udbyttehistorik: 23 år.

Ex-DatoUdbetalingBeløb%TypeTicker
2026-05-062026-05-074.1200 EUR5.4/5.4 %årligUS:SNYNF
2025-05-132025-05-143.9200 EUR4.1/4.1 %årligUS:SNYNF
2024-05-132024-05-153.7600 EUR4.0/4.0 %årligUS:SNYNF

Største Ejere

EjerAndelAktierRapportdato
Dodge & Cox Inc.10.54%28.09 mio.2026-06-30
Dodge & Cox Funds-Dodge…7.84%20.9 mio.2026-06-30
Morgan Stanley4.02%10.7 mio.2026-06-30
Fisher Asset Management,…3.99%10.63 mio.2026-06-30
Bank of America Corporat…3%8.01 mio.2026-06-30
Invesco Ltd.2.55%6.8 mio.2026-06-30
JPMORGAN CHASE & CO2.47%6.57 mio.2026-06-30
Mondrian Investment Part…2.07%5.52 mio.2026-06-30
Brandes Investment Partn…1.55%4.14 mio.2026-06-30
AIM Sector Funds (Invesc…1.51%4.03 mio.2026-04-30
Federated Hermes, Inc.1.44%3.85 mio.2026-06-30
Boston Partners1.44%3.84 mio.2026-06-30
VANGUARD STAR FUNDS-Vang…1.31%15.85 mio.2026-07-31
Putnam ETF Trust-Putnam…1.26%3.36 mio.2026-05-31
VANGUARD TAX-MANAGED FUN…0.87%10.53 mio.2026-06-30
iShares Trust-iShares Co…0.67%8.11 mio.2026-08-31
Dodge & Cox Funds-Dodge…0.63%1.67 mio.2026-06-30
AMERICAN MUTUAL FUND0.59%1.58 mio.2026-06-30
American Century Capital…0.37%976 5612026-06-30
Bridge Builder Trust-Bri…0.36%967 1002026-06-30
Fidelity Concord Street…0.35%4.24 mio.2026-07-31
VanEck ETF Trust-VanEck…0.35%938 5612026-08-31
Dodge & Cox Funds-Dodge…0.33%4.04 mio.2026-06-30
iShares Trust-iShares MS…0.32%3.89 mio.2026-08-31
Capital World Growth & I…0.3%3.67 mio.2026-06-30
-Victory Pioneer Core Eq…0.3%799 4872026-06-30
Fidelity Covington Trust…0.3%797 1842026-08-31
NEW PERSPECTIVE FUND0.29%3.56 mio.2026-06-30
Federated Hermes Eqy. Fd…0.29%3.48 mio.2026-07-31
Bridge Builder Trust-Bri…0.29%3.44 mio.2026-06-30
Pacer Advisors, Inc.0.1%1.16 mio.2026-06-30
Generali Investments Cee…0%29 3392026-06-30
Paradigm Asset Managemen…0%19 2002026-06-30
Gamma Investing LLC0%582026-06-30
L'Oréal———